IFRX InflaRx N.V. Stock Quote

IFRX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.25	Insider Own	14.89%	Shs Outstand	44.19M	Perf Week	7.17%
Market Cap	223.47M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	0.00%	Shs Float	37.61M	Perf Month	77.62%
Income	-47.50M	PEG	-	EPS next Q	-0.29	Inst Own	20.90%	Short Float	2.31%	Perf Quarter	98.44%
Sales	-	P/S	-	EPS this Y	38.70%	Inst Trans	-18.66%	Short Ratio	0.29	Perf Half Y	66.56%
Book/sh	2.96	P/B	1.72	EPS next Y	-9.10%	ROA	-33.50%	Target Price	9.58	Perf Year	28.61%
Cash/sh	2.43	P/C	2.09	EPS next 5Y	-	ROE	-36.70%	52W Range	2.23 - 6.88	Perf YTD	0.99%
Dividend	-	P/FCF	-	EPS past 5Y	-43.00%	ROI	-	52W High	-26.16%	Beta	0.75
Dividend %	-	Quick Ratio	7.70	Sales past 5Y	-	Gross Margin	-	52W Low	127.80%	ATR	0.53
Employees	49	Current Ratio	7.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	62.07	Volatility	10.73% 13.61%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-10.30%	Profit Margin	-	Rel Volume	0.44	Prev Close	5.02
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	2.98M	Price	5.08
Recom	2.40	SMA20	6.09%	SMA50	45.30%	SMA200	49.20%	Volume	1,325,178	Change	1.20%

Oct-28-21

Upgrade

Raymond James

Outperform → Strong Buy

$10 → $14

Mar-11-21

Upgrade

Guggenheim

Neutral → Buy

$16

Nov-06-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$7 → $10

Oct-08-20

Initiated

H.C. Wainwright

Buy

$11

Jun-17-20

Initiated

BTIG Research

Buy

$12

Apr-30-20

Upgrade

Raymond James

Mkt Perform → Outperform

Jun-05-19

Downgrade

SunTrust

Buy → Hold

$55 → $5

Jun-05-19

Downgrade

Robert W. Baird

Outperform → Neutral

$58 → $6

Jun-05-19

Downgrade

JP Morgan

Overweight → Underweight

$67 → $9

Jun-05-19

Downgrade

Guggenheim

Buy → Neutral

$65 → $6

Jun-05-19

Downgrade

BMO Capital Markets

Outperform → Market Perform

Jan-29-19

Initiated

Robert W. Baird

Outperform

Dec-10-18

Initiated

Credit Suisse

Outperform

Jul-13-18

Initiated

BMO Capital Markets

Outperform

$45

Jun-28-18

Initiated

SunTrust

Buy

$55

Jun-28-18

Initiated

Raymond James

Outperform

Feb-08-18

Initiated

B. Riley FBR, Inc.

Buy

$40

Nov-15-21 03:39PM	InflaRx's Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder Benzinga -12.19%
07:30AM	InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV) GlobeNewswire
Nov-11-21 07:30AM	InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference GlobeNewswire +5.14%
Nov-08-21 06:17AM	Calculating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX) Simply Wall St.
Nov-05-21 07:30AM	InflaRx Reports Third Quarter 2021 Financial & Operating Results GlobeNewswire
Nov-03-21 07:30AM	InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference GlobeNewswire
Oct-28-21 09:51AM	Why InflaRx Shares Are Ripping Higher Thursday Benzinga +41.96%
09:49AM	InflaRx stock rockets on heavy volume after positive trial data on PG treatment prompts analyst upgrade MarketWatch
07:10AM	30 Stocks Moving in Thursday's Pre-Market Session Benzinga
07:03AM	InflaRx Stock Upgraded after Positive Data from Phase 2 Study Investing.com
Oct-27-21 07:30AM	InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum GlobeNewswire
Oct-19-21 10:08AM	Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Boosts FY21 Guidance Benzinga +14.46%
07:30AM	InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19 GlobeNewswire
Oct-12-21 07:30AM	InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19 GlobeNewswire -5.14%
Sep-09-21 07:30AM	InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-08-21 07:30AM	InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint GlobeNewswire
Aug-10-21 09:17AM	InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer Patients Benzinga
07:30AM	InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum GlobeNewswire
Aug-06-21 07:30AM	InflaRx to Present at the BTIG Virtual Biotechnology Conference GlobeNewswire
Aug-05-21 07:30AM	InflaRx Reports Second Quarter 2021 Financial & Operating Results GlobeNewswire
Jul-28-21 03:45PM	Were Hedge Funds Right About InflaRx N.V. (IFRX)? Insider Monkey
Jun-17-21 07:30AM	InflaRx to Present at the Raymond James Human Health Innovation Conference GlobeNewswire
Jun-08-21 07:30AM	InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab GlobeNewswire
May-30-21 05:22AM	We're Hopeful That InflaRx (NASDAQ:IFRX) Will Use Its Cash Wisely Simply Wall St.
May-21-21 07:30AM	Tony Gibney Joins InflaRx Board of Directors GlobeNewswire
May-12-21 07:30AM	InflaRx Reports First Quarter 2021 Financial & Operating Results GlobeNewswire -17.87%
07:15AM	InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study Benzinga
May-11-21 04:30PM	InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study GlobeNewswire
Apr-15-21 07:30AM	InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum GlobeNewswire
Mar-25-21 06:30AM	InflaRx Reports Full Year 2020 Financial & Operating Results GlobeNewswire
Mar-03-21 07:30AM	InflaRx to Present at Upcoming Investor Conferences GlobeNewswire -6.06%
Mar-01-21 04:01PM	InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants GlobeNewswire
01:54AM	What Kind Of Investors Own Most Of InflaRx N.V. (NASDAQ:IFRX)? Simply Wall St.
Feb-25-21 08:30AM	InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants GlobeNewswire -14.96%
Feb-24-21 04:01PM	InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants GlobeNewswire
Feb-11-21 09:11AM	InflaRx's Vilobelimab Suppresses Inflammation In Mid-Stage Chronic Skin Disorder Study Benzinga
07:30AM	InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference GlobeNewswire
Jan-11-21 07:30AM	InflaRx Provides Update on Vilobelimab (IFX-1) Development GlobeNewswire
Jan-07-21 07:30AM	InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-05-21 07:30AM	InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis GlobeNewswire +12.06%
Dec-08-20 11:35AM	These 2 Penny Stocks Could Surge Over 200%, Says Raymond James TipRanks +18.27%
Dec-02-20 08:30PM	Hedge Funds Are Dumping InflaRx N.V. (IFRX) Insider Monkey
Nov-12-20 07:02AM	Will InflaRx (NASDAQ:IFRX) Spend Its Cash Wisely? Simply Wall St.
Oct-29-20 07:00AM	InflaRx Reports Q3 2020 Financial & Operating Results GlobeNewswire +7.29%
Sep-30-20 04:22AM	InflaRx Pops 6% On Promising Data From Covid-19 Therapeutic Trial SmarterAnalyst -7.19%
Sep-17-20 07:30AM	InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer GlobeNewswire
Sep-14-20 07:30AM	InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia GlobeNewswire +16.09%
Aug-06-20 07:30AM	InflaRx to Present at Upcoming Virtual Investor Events GlobeNewswire
Jul-30-20 07:30AM	InflaRx Reports Q2 2020 Financial & Operating Results GlobeNewswire
Jul-24-20 08:55AM	Are Options Traders Betting on a Big Move in InflaRx (IFRX) Stock? Zacks
Jul-21-20 07:30AM	InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia GlobeNewswire
Jul-16-20 11:48AM	What Kind Of Shareholders Hold The Majority In InflaRx N.V.'s (NASDAQ:IFRX) Shares? Simply Wall St. +11.18%
Jul-09-20 07:33AM	InflaRx Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-25-20 04:05PM	Hedge Funds Are Buying InflaRx N.V. (IFRX) Insider Monkey
Jun-17-20 07:30AM	InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19 GlobeNewswire -25.07%
Jun-11-20 08:30AM	InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions Zacks -11.17%
May-29-20 11:10AM	The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin Zacks
May-28-20 08:31AM	Europe Equities Are Hot on Stimulus Optimism: 5 Picks Zacks +7.05%
May-21-20 07:30AM	InflaRx Reports Q1 2020 Financial & Operating Results GlobeNewswire +7.77%
Apr-29-20 08:00AM	InflaRx Reports Full Year 2019 Financial & Operating Results GlobeNewswire -6.55%
Apr-14-20 07:30AM	We're Hopeful That InflaRx (NASDAQ:IFRX) Will Use Its Cash Wisely Simply Wall St.
Apr-01-20 04:18PM	Covid Report: Testing News Sends One Biotech Flying As Another Dives Investor's Business Daily +50.00%
07:38AM	The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests Benzinga
Mar-31-20 04:15PM	InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology GlobeNewswire +8.22%
Mar-06-20 10:49AM	4 Smaller, Cash-Rich Biotech Stocks That Could Be Havens Barrons.com +7.45%
Feb-26-20 07:30AM	InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum GlobeNewswire +16.03%
Feb-19-20 08:00AM	InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference GlobeNewswire +13.84%
Jan-09-20 07:30AM	InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference GlobeNewswire +5.51%
Dec-20-19 07:45PM	Did Hedge Funds Drop The Ball On InflaRx N.V. (IFRX) ? Insider Monkey
Nov-07-19 07:30AM	InflaRx Reports Third Quarter 2019 Financial & Operating Results ACCESSWIRE +5.79%
07:18AM	The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
02:10AM	InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa ACCESSWIRE
Oct-17-19 08:43AM	Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation Simply Wall St.
Aug-14-19 04:05PM	InflaRx Reports Second Quarter 2019 Financial & Operating Results GlobeNewswire
Jul-19-19 12:43PM	Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)? Simply Wall St.
Jul-18-19 04:01PM	InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa GlobeNewswire
09:55AM	InflaRx Enters Oversold Territory Zacks
Jun-29-19 11:31PM	Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX) Insider Monkey
Jun-13-19 10:18AM	InflaRx Enters Oversold Territory Zacks
09:00AM	InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum GlobeNewswire
Jun-05-19 04:18PM	InflaRx shares plummet over 90% after drug test failure Yahoo Finance Video -91.79%
07:49AM	InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa GlobeNewswire
May-23-19 09:15AM	InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:00AM	InflaRx Reports First Quarter 2019 Financial & Operating Results GlobeNewswire
May-14-19 08:00AM	InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe GlobeNewswire
May-03-19 10:12AM	Did Hedge Funds Drop The Ball On InflaRx N.V. (IFRX)? Insider Monkey
Apr-10-19 08:45AM	InflaRx (IFRX) Catches Eye: Stock Jumps 7.5% Zacks +7.38%
Mar-28-19 08:30AM	InflaRx Full Year 2018 Financial & Operating Results GlobeNewswire
Mar-12-19 07:37AM	InflaRx (NASDAQ:IFRX) Shareholders Booked A 63% Gain In The Last Year Simply Wall St.
Feb-27-19 08:30AM	InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum GlobeNewswire +5.81%
Feb-25-19 07:30AM	Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-14-19 08:30AM	Richard Brudnick to Join InflaRx Board of Directors GlobeNewswire
Feb-06-19 07:00AM	InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa GlobeNewswire
Jan-03-19 08:30AM	InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management GlobeNewswire
Dec-22-18 03:43AM	Is InflaRx N.V. (IFRX) A Good Stock To Buy? Insider Monkey
Dec-19-18 08:30AM	InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis GlobeNewswire
Nov-21-18 08:30AM	InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results GlobeNewswire
Nov-08-18 02:30AM	InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa GlobeNewswire
Oct-30-18 07:30AM	InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing GlobeNewswire
Oct-23-18 09:15AM	Factors of Influence in 2018, Key Indicators and Opportunity within Dropbox, Kura Oncology, DHT, Wayfair, US Foods Holding, and InflaRx N.V New Research Emphasizes Economic Growth GlobeNewswire

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience